Active ingredientBrilanestrantCat. No. P-B107-001CAS 1365888-06-7Family · Pharmaceutical analytical standards
Brilanestrant
A non-steroidal selective oestrogen receptor degrader (SERD), studied for advanced or metastatic oestrogen receptor-positive breast cancer; it reached phase II clinical trials, and its development was discontinued in 2017. This family brings together the active ingredient.
Did you know?Unlike fulvestrant, which is given by intramuscular injection, it is active by mouth; chemically it is an analogue of etacstil, a similar compound abandoned in 2001.
Go to the active ingredient →Active ingredientBrilanestrantCat. No. P-B107-001CAS 1365888-06-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.